Conestoga Capital Advisorsasset management company, released an investor letter for the first quarter of 2026. A copy of the book can be downloaded here. The first quarter of 2026 started optimistically with the domestic economy and attractive Small Cap ratings, but was affected by volatility from the turmoil in the Middle East and changing interest rate expectations. The turmoil has driven up energy prices and created cautious global markets. Energy, Basic Materials, and Industrials performed well, while software companies faced challenges due to AI disruption concerns. Market sensitivity to global events, energy prices, and inflation remains high. The Conestoga Small Cap Composite fell 5.01%, underperforming the Russell 2000 Growth’s -2.81% return. The decline was fueled by poor stock selection and headwinds in technology and Healthcare, while sector allocation gains were not enough to offset losses. In addition, please check the top five Strategy items to know your best choice in 2026.
In its investor letter for the first quarter of 2026, Conestoga Capital Advisors highlighted stocks like Stevanato Group SpA (NYSE:STVN). Stevanato Group SpA (NYSE:STVN) is an Italian company that designs and distributes products and processes to provide integrated solutions for the biopharma and healthcare industries. On April 24, 2026, Stevanato Group SpA (NYSE:STVN) closed at $16.18 per share. Stevanato Group SpA (NYSE:STVN)’s one-month return was 20.12%, and its shares lost 25.02% in the last 52 weeks. Stevanato Group SpA (NYSE:STVN) has a market capitalization of about $4.42 billion.
Conestoga Capital Advisors said the following about Stevanato Group SpA (NYSE:STVN) in its Q1 2026 investor note:
Stevanato Group SpA share price (NYSE:STVN) provides container and drug solutions to pharmaceutical and biotechnology companies. The stock struggled as investors weighed strong results against the company’s underlying business mix and growth profile for the equity. While margins improved and higher value solutions continued to grow, overall revenue growth remained a meager 5% for the quarter. Continued weakness in the engineering sector and the shift to higher value products contributed to the aggressive market reaction. The stock is also pressured by the decline of oral vs. GLP-1s.”
Stevanato Group SpA (NYSE:STVN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds Entering 2026. According to our data, 15 hedge fund portfolios held Stevanato Group SpA (NYSE:STVN) at the end of the fourth quarter, up from 13 last quarter. In Q4 2025, Stevanato Group SpA (NYSE:STVN) revenue grew 7% on a constant currency basis and 5% on a reported basis to $346.5 million. While we recognize the potential of Stevanato Group SpA (NYSE:STVN) as an investment, we believe certain AI stocks offer greater potential and carry less downside risk. If you’re looking for an extremely overlooked AI stock that will benefit greatly from the Trump-era costs and sea trend, check out our free report best short term AI stock.
